Data from five European countries in 2010 show that spending on diabetes medicines (insulin and oral medicines for diabetes) was between 6.2% (France and Italy) and 10.5% (Spain) of total direct cost of diabetes care.22 The gene discussed is INS; the disease is diabetes mellitus.